gbola amusa md cfa head hc research
sale trade et
sale trade et
viral news genet medicin data qure hemb hema isth
highlight week june juli uniqur buy chardan top pick present
intern societi thrombosi haemostasi isth annual congress melbourn follow-up result
phase iib trial gene therapi gt long-term follow-up result
phase i/ii trial gt hemophilia hemb data phase iib
trial show sustain increas factor ix activ week post-treat vc/kg
mean activ patient activ normal rang patient experienc
materi loss activ month result roughli similar data phase i/ii trial show
sustain reduct mean annual bleed rate abr year post-treat patient
high dose cohort gc/kg compar year prior treatment unrat
unrat present isth annual congress updat result alta phase i/ii trial
gt hemophilia hema data patient demonstr dose-depend increas
factor viii fviii level decreas fviii replac therapi gener well-toler
previous disclos seriou advers event sae hypotens fever report base data alta
studi recent grant regen medicin advanc therapi rmat design fda
amicu neutral enter develop manufactur agreement
unrat catal biolog unrat paragon gene therapi unit thermo fisher agreement encompass
amicu aav-bas gt program batten diseas agreement encompass amicu aav-bas
gt program lysosom storag diseas compani collabor univers pennsylvania
includ fabri diseas pomp diseas
look forward juli juli juli intern societi thrombosi haemostasi isth
annual congress melbourn continu program includ repres biomarin pharmaceut
unrat uniqur
weekli price move vivo genet medicin aav srna mrna vivo gene edit
upcom chardan genet medicin event contact chardan rsvp
genet medicin news june juli
buy announc appoint david nassif cfo expans board director juli
buy announc submiss ema givosiran treatment ahp juli
unrat present new data cure sma confer nurtur studi spinraza juli
unrat announc gt licens agreement odylia therapeut privat juli
buy announc ad russel juli
buy publish collabor uwashington predict utr mrna juli
unrat publish allele-specif gene regul via zfp-tf hd model juli
cyad unrat provid updat autolog car-t tx program r/r aml md juli
neutral announc gt develop manufactur collab thermo fisher unrat juli
pleas refer import disclosur inform regul analyst certif found page report
neutral announc gt develop manufactur collab unrat juli
buy announc submiss cta applic pi/ii trial rnai tx aatd juli
abu buy announc sale part royalti interest rnai tx onpattro juli
buy announc mm debt facil secur oxford financ llc juli
umrx unrat announc clinic hold pi trial cell-bas actr tx r/r nhl juli
univers nebraska publish tx clear hiv infect mice juli
uc berkeley receiv patent relat juli
unrat announc appoint dr drew denig director tcr-t cell tx program juli
harvard publish allele-specif gene edit mous model deaf juli
cyad unrat present esmo data phase trial solid tumor juli
freelin privat present ewggd preclin data aav-bas gt gaucher diseas juli
unrat present unrat result p/ii trial gt hema juli
sangamo present isth annual congress updat result alta phase i/ii trial
gt hema sangamo develop plan advanc
registr studi assum respons late-stag manufactur develop
data present includ patient treat infus vg/kg vg/kg
vg/kg vg/kg patient demonstr dose-depend increas factor viii fviii
level decreas use fviii replac therapi vg/kg cohort fviii level durabl
week vg/kg cohort fviii level normal rang durabl latest measur
time point patient week post-treat remain patient fviii kinet parallel
patient respect time point week post-treat patient vg/
kg cohort experienc bleed fviii replac therapi data cut-off
gener well toler patient treat prophylact steroid treatment-rel sae
report patient experienc hypotens fever hour post-treat resolv
treatment within hour sae previous disclos april data patient patient
experienc elev alanin aminotransferas alt level associ loss fviii express although
patient vg/kg cohort experienc grade baselin alt elev resolv taper
cours oral steroid
base data alta studi grant regen medicin advanc therapi rmat
design fda data demonstr continu durabl patient high dose cohort
beyond data report april potenti similar trajectori new patient treat cohort plan
advanc registr studi underway note unrat may
report interim result phase trial gt valrox met criteria regulatori submiss
plan announc time file hema
qure buy present isth result trial hemb juli
uniqur present isth annual congress follow-up data phase iib trial
long-term follow-up data phase i/ii trial hemb
phase iib studi patient show low level neutral antibodi
nab treat iv infus vc/kg week post-treat patient
experienc bleed event requir replac therapi patient hip replac surgeri
treat periop short-act factor replac report sae unrel
data follow data report may see research month post-treat
week post-treat patient show sustain increas activ measur use activ partial
thromboplastin time aptt assay patient activ normal rang mean activ
normal slight decreas normal month post-treat despit decreas mean
activ remain high end estim rang week post treatment outlin
uniqur octob corpor present see slide previous note decemb
research saw possibl could perform beyond estim rang
phase i/ii studi patient treat iv infus gc/kg
gc/kg year post-treat patient high dose cohort remain free routin
page
replac therapi last month post-treat mean abr bleed reduct
year prior treatment steady-st mean yearli activ year post-treat compar
first year second year
compani mention report
page
select catalyst genet medicin coverag
figur alnylam arrowhead dicerna meira gtx expect initi trial
select optim dose xlmtm
dcr-phxc initi long-term registr roll-ov studi ph
file ind cta pomp diseas
aro-aat initi phase ii/iii studi liver diseas
releas cgmp manufactur phase i/ii studi
initi phase i/ii trial
aav-rpgr prelim dose escal data phase i/ii trial xlrp
initi trial malign
complet ind-en studi diseas
dose patient phase studi mp
lumasiran initi illuminate-b -c phase trial
provid updat phase i/ii studi hemophilia
report phase i/ii data
page
select catalyst genet medicin coverag
file ind pomp diseas
inclisiran report top-line data orion studi hypercholesterolemia
initi phase i/ii clinic trial huntington diseas
report dose escal data pi/ii trial achm/xlrp
report preliminari data phase i/ii studi batten diseas
initi phase i/ii trial dmd
submit ema lhon
report interim efficaci readout phase oval trial ovarian cancer
xlrp report interim data expans arm phase i/ii trial xlrp
dcr-hbv anticip first interim data clinic trial hbv
provid initi data phase trial gangliosidosi
provid earli data cohort phase i/ii pioneer trial n- rp
file ind phase ii studi diabet retinopathi dr
present interim data pi/ii studi mp ii pi studi mp
present interim data cohort steroid prophyl pi/ii studi hofh
file ind batten diseas
top-lin phase ii data treat deb patient chronic wound
initi phase i/ii trial autosom recess congenit ichthyosi
report interim phase i/ii data rix nidcr/nih
initi dose phase trial hemophilia
initi phase i/ii trial
initi phase iib studi wet
lumasiran present top-line data illuminate-a phase trial
vutrisiran initi helios-b phase studi cardiomyopathi attr amyloidosi
inclisiran file nda hypercholesterolemia
updat dose escal pi/ii ignit trial dmd
provid updat initi safeti studi hemophilia without inhibitor
 aro-enac file clear cell renal cell carcinoma cystic fibrosi
 fc initi phase ii/iii trial newli diagnos glioblastoma
 fc safeti activ readout phase ib trial met solid tumor
submit ind methylmalon acidemia mma
present preclin data new gt program fabri pomp defici
initi phase i/ii trial sjogren syndrom
file ind initi phase i/ii trial al
file ind initi phase i/ii trial wet
file ind huntington diseas program
provid follow-up data piib dose-confirm studi hemb
present top-lin data phase i/iia clinic trial wet
initi pivot trial
 fc report final analysi phase trial rhgg
declar develop candid aml
initi phase trial dystroph epidermolysi bullosa deb
figur alnylam/mdco meira gtx solid uniqur expect import data read-out
page
select catalyst outsid genet medicin coverag
file ind rett syndrom
initi phase trial recess dystroph epidermolysi bullosa
nsr-rpgr provid follow-up data phase xiriu dose escal studi xlrp
file ind inherit amyotroph later sclerosi
begin patient dose phase trial
initi pivot phase trial rdeb
dtx provid phase i/ii cohort data ornithin transcarbamylas defici
dtx provid pi/ii cohort data glycogen storag diseas type ia gsdia
valrox present full piii top-line data hem
nsr-rpgr provid prelim data expans cohort phase ii/iii trial xlrp
zolgensma anticip approv eu
initi phase ii trial /- cemiplimab cutan squamou cell carcinoma
initi phase trial /- solid tumor
nsr-rpgr report follow-up data open label dose escal phase xiriu studi
present data phase portion solid tumor trial /- nivolumab
valrox submit bla pend fda feedback hemophilia
begin dose patient investigator-sponsor phase i/ii trial cystinosi
initi phase i/ii trial type gaucher diseas
bmn file ind phenylketonuria pku
initi phase i/ii trial leukocyt adhes deficiency-i
initi phase ib trial beta-thalassemia
initi phase ii/iii trial dmd
initi phase studi pyruv kinas defici pkd
initi phase trial multipl myeloma
initi clinic trial charcot-marie-tooth type
file approv transit clinic trial platform manufactur
rituximab report preliminari phase cohort expans data r/r nhl
micro-dystrophin initi pivot trial duchenn muscular dystrophi
hmaxi-k initi phase ii studi overact bladder
initi phase i/ii trial gangliosidosi
zolgensma complet strong phase trial pre-symptomat sma type
initi phase i/ii studi best diseas
micro-dystrophin initi confirmatori trial commerci materi dmd
tegsedi expect approv brazil hattr amyloidosi
 anticip data readout phase trial hd
ptc-aadc file bla aromat l-amino acid decarboxylas aadc defici
ptc-fa file ind friedreich ataxia fa enter clinic
sea-bcma report preliminari phase dose escal data r/r mm
lentiglobin initi phase studi sickl cell diseas
figur plan file bla aadc defici
page
corpor report factset chardan note mention stock unrat unless state select public gm compani includ adhera therapeut
benitec biopharma fibrocel buy lysogen oncosec medic oxford biomedica buy vbl neutral
figur select price movement week end juli vivo gm perform aav srna mrna ivg
page
week-over-week perform vivo genet medicin aav srna mrna vivo gene edit basketstickerratingccm ptupsideclosechang changemc mm genet medicin cap genet medicin vivo cap genet medicin ex vivo cap gene therapytickerratingccm ptupsideclosechang changemc mm gensight genet therapytickerratingccm ptupsideclosechang changemc mm miragen gene editingtickerratingccm ptupsideclosechang changemc mm pharmaceut
vivo genet medicin monthli market cap progress select compani
corpor report factset chardan note though avx nite acquir continu includ exhibit reflect valu creation sub-sector
figur aav-bas gene therapyend-monthli market cap select compani januari present
figur srna mrna therapyend-monthli market cap select compani januari present
figur vivo gene editingend-monthli market cap select compani januari present
page
cap million aav gt sector market cap cap million srna mrna gt sector market cap cap million vivo gene edit sector market cap
aav-bas gene therapi comp meiragtx uniqur chardan top pick
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrat name model current market cap
refer partner product avexi novarti compani wet hofh mp mp ii phase i/ii trial
figur select public aav-bas gene therapi companiesw prefer buy buy qure buy greater potenti drive upsid aav gt space
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof genet technolog privat aav-bas genetherapi molecular ask estev horama stride tamid
srna mrna therapi comp alnylam top pick
corpor report factset chardan note mention stock unrat unless state target market cap unrat name rgl model current market cap
figur select public srna mrna therapi companiesw prefer buy buy greater potenti drive upsid entir srna mrna space
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitalnylam privat srna mrna therapi companiesadvirna silense sirnaom somagen sylenti ntech curevac ethri etherna immunotherapi genev scienc strand note adhera benitec pharma silenc addit unrat public compani
vivo gene edit comp see greater upsid potenti intellia toolgen
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrat name model current market cap
figur vivo gene editingw broadli expect out-performance crispr sector higher potenti perform buy toolgen buy
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitcrispr privat vivogen edit companiesbeam egenesi excis exon feldan recombinet
genet medicin therapeut approv posit opinion fda and/or ema
date
date
corpor report fda ema chardan note market author glybera expir due uniqur decis appli renew exclud antisens oligonucleotid figur
figur believ recent increas rate approv posit opinion genet medicin sign sector rapidli emerg
page
genet medicin therapeut receiv fda breakthrough therapi ema prime design
date fda btd
date ema prime
hattr amyloidosi polyneuropathi
corpor report fda ema biopharm insight chardan note ema start grant prime design may fda start grant breakthrough therapi design juli
figur believ disproportion amount btd prime design award genet medicin anoth sign sector rapidli emerg
page
date fda rmat
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur regen medicin advanc therapi design allow compani interact fda earlier clinic test process frequent
prioriti review voucher prv valu prv sold compani compani
date prv sale
ultragenyx undisclos
spark
ultragenyx novarti
biomarin undisclos
sarepta gilead
unit abbvi
sanofi
knight gilead
biomarin sanofi/regeneron pharmaceut
figur prioriti review voucher prv sold million million
price prv
page
date fda rpdd
corpor report fda biopharm insight chardan note list rpdd may incomplet sinc exampl compani disclos regulatori design
figur sinc pediatr diseas design potenti lead prioriti review voucher drug approv hidden sourc valu exist compani
page
date fda ftd
crispr vertex
crispr vertex
rp due mutat exon gene
moder sever local scleroderma
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
date fda ftd
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
genet medicin select therapeut receiv btd rmat prime rpdd and/or ftd us eu
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genet medicin regulatori design btd rmat prime ftd rpdd grant time
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design ema start grant prime design may
fda start grant breakthrough therapi design btd juli pediatr diseas design rpdd rmat design genet medicin began novemb
figur regulatori design btd rmat prime ftd rpdd grant genet medicin consider increas grant
page
designationsyear design grantedgenet medicin regulatori design ytd btdrmatprimeftdrpdd biotechnolog pharmaceut
